Bangladesh embarks on monitoring Anti-Microbial Consumption (AMC)
Antimicrobial therapies – such as antivirals and antibiotics – have played an essential role in the treatment of infections in humans and animals and have significantly improved public health. The recent rise in resistance to antimicrobials threatens the very core of modern medicine and the sustainability of an effective, global public health response to the enduring threat from infectious diseases.
As part of Bangladesh’s efforts to combat antimicrobial resistance, a national system for monitoring the consumption (AMC) of antimicrobials in the country is currently under establishment. To achieve this, WHO Country Office for Bangladesh in collaboration with Directorate General of Drug Administration (DGDA) conducted a National Workshop on Monitoring Antimicrobial Consumption in august 2017. The workshop gathered different stakeholders with a potential involvement in monitoring antimicrobial consumption. Participants included Directorate General of Health Services (DGHS), Development Partners- MSH/SIAPS, USP/PQM, USAID, DFID, FAO, UNICEF and GARP. The event also involved academia, public, private and autonomous organizations as well as Medical specialty groups and owners association for veterinary goods.
Following the workshop, a national task force to oversee the activities was formed, chaired by Director General, DGDA, and with involvement of concerned public and private organizations. The conceptual framework for the national AMC monitoring system has been developed. Through several task force meetings, a methodology has been adapted from the WHO global methodology for monitoring AMC. Data collection will commence in 2018.